Lataa...
Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
BACKGROUND: There is no standard therapy for second-line treatment of gemcitabine-refractory pancreatic cancer patients with poor performance status. A combination of chemotherapy drugs 5-fluorouracil (5-FU), leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or 5-fluorouracil/leucovorin plus nano...
Tallennettuna:
| Julkaisussa: | World J Gastrointest Oncol |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Baishideng Publishing Group Inc
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6883178/ https://ncbi.nlm.nih.gov/pubmed/31798782 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4251/wjgo.v11.i11.1021 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|